Peer-influenced content. Sources you trust. No registration required. This is HCN.

Trending Topics:
DIET & NUTRITION PATIENT EDUCATION OBESITY/WEIGHT MANAGEMENT EXERCISE/TRAINING LEGAL MATTERS GUIDELINES/RECOMMENDATIONS

Articles related to MOVEMENT DISORDERS

Parkinson’s News Today

FDA Grants Advanced Therapy Status to Parkinson’s Cell Treatment

Twelve months after transplantation with the lower dose, mean scores decreased by 30.6 points during off time (a 52.82% improvement from baseline) and by 12.9 points during on time (a 54.67% improvement).

Geriatrics February 5th 2026

Tags: FDA MOVEMENT DISORDERS NEUROSURGERY PARKINSON'S DISEASE (PD) REGULATORY AFFAIRS

MDLinx

Ozzy Osbourne’s Parkinson’s Wasn’t Typical—and Neither Was His Decline

This combination of Parkinsonism and polytrauma provides a powerful example of how neurodegeneration can be compounded by structural damage, with each element worsening the other.

Geriatrics August 20th 2025

Tags: CELEBRITY DIAGNOSIS MOVEMENT DISORDERS NEURODEGENERATIVE DISEASES PARKINSON'S DISEASE (PD)

Medical Professionals Reference (MPR)

FDA Clears AI-Powered Wristband Device for Patients with Essential Tremor

This breakthrough in noninvasive, intelligent, and personalized neuromodulation marks the emergence of AI therapeutics in disease treatment.

Neurology July 23rd 2025

Tags: ARTIFICIAL INTELLIGENCE (AI) DEVICE/DRUG APPROVALS ESSENTIAL TREMOR (ET) MOVEMENT DISORDERS WEARABLES

Parkinson’s News Today

Mitochondrial Dysfunction Partly Explained by Immune Responses

Blood-based mitochondrial DNA testing could provide a less invasive alternative to spinal taps for Parkinson’s diagnosis, with implications for earlier intervention and treatment.

Allergy & Immunology January 22nd 2025

Tags: BIOMARKERS MEDICAL DIAGNOSTICS MOVEMENT DISORDERS PARKINSON'S DISEASE (PD) TESTING/LABS

Neurology Learning Network

New Restless Leg Syndrome Guidance Reverses Some Previous Recommendations

Long-term use of dopaminergic medications shows correlation with gradual RLS symptom deterioration, prompting a shift toward alpha-2-delta ligand calcium channel blockers as preferred pharmacological interventions.

Family Medicine/General Practice January 8th 2025

Tags: GUIDELINES/RECOMMENDATIONS INSOMNIA/SLEEP DISORDERS MOVEMENT DISORDERS PATIENT CARE

Psych Congress Network

Overview of Anticholinergic Medications

Anticholinergic medications require careful consideration of both peripheral and central effects, particularly in patients with existing cognitive impairments.

Family Medicine/General Practice December 11th 2024

Tags: COGNITIVE HEALTH/MEMORY DRUG SAFETY & INTERACTIONS GUIDELINES/RECOMMENDATIONS MOVEMENT DISORDERS PSYCHOPHARMACOLOGY

Topics

Sources

American Journal of Clinical Pathology (AJCP)
American Nurse Journal (ANJ)
Annals of Internal Medicine
BlackDoctor.org (BDO)
Blood Cancers Today (BCT)
British Medical Journal (The BMJ)
Cancer Therapy Advisor
Cardiology
Cardiology Advisor
Cleveland Clinic Journal of Medicine (CCJM)
Clinical Advances in Hematology & Oncology
Clinical Infectious Diseases (CID)
Cureus
Epoch Health
GoodRx for Healthcare Professionals
Health
Healthgrades for Professionals
HealthLeaders
Healthline
Journal of the American College of Cardiology (JACC)
Journal of Invasive Cardiology (JIC)
Journal of the National Cancer Institute (JNCI)
The Journal of Sexual Medicine
Mayo Clinic
MDLinx
MedCentral
Medical News Today (MNT)
Medical Professionals Reference (MPR)
Neurology Advisor
Northwestern Medicine
Oncology News Central (ONC)
Physician’s Weekly
Practical Neurology
Psychiatrist.com
Psychiatry Advisor
ReachMD
Sharecare
SingleCare
UCLA Health
Verywell Health
Verywell Mind
WebMD
Women’s Healthcare
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form